0001140361-11-024791.txt : 20110504
0001140361-11-024791.hdr.sgml : 20110504
20110504122617
ACCESSION NUMBER: 0001140361-11-024791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110503
FILED AS OF DATE: 20110504
DATE AS OF CHANGE: 20110504
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: THERAVANCE INC
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 901 GATEWAY BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508086000
MAIL ADDRESS:
STREET 1: 901 GATEWAY BLVD
CITY: S. SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 11809097
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
4
1
doc1.xml
FORM 4
X0303
4
2011-05-03
0
0001080014
THERAVANCE INC
THRX
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
0
0
1
0
Common Stock
2011-05-03
4
P
0
261299
25.60
A
6163577
I
By Corporation
Common stock purchased pursuant to the right of GlaxoSmithKline LLC ("GSK LLC") under Section 2.1(d)(ii) of the Amended and Restated Governance Agreement by and among Theravance, Inc. (the "Issuer"), GSK LLC and GlaxoSmithKline plc dated as of June 4, 2004, as amended. Pursuant to Section 2.1(d)(ii), GSK LLC has the right to purchase from the Issuer, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity.
The amount of Common Stock reported as beneficially owned by the Reporting Person following the reported transaction does not include the Reporting Person's previously disclosed beneficial ownership of 9,401,499 shares of Class A Common Stock of the Issuer (the "Class A Common Stock"), which are held of record by GSK LLC and Glaxo Group Limited ("GGL"), each of which is a wholly-owned subsidiary of the Reporting Person. Each share of Class A Common Stock may be converted into one share of Common Stock at any time.
Shares of Common Stock are held of record by GGL.
/s/ Victoria A. Whyte, Company Secretary
2011-05-04